263
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

In response to: “Loperamide metabolite-induced cardiomyopathy and QTc prolongation”

, &
Page 1023 | Received 16 May 2017, Accepted 19 May 2017, Published online: 15 Jun 2017

References

  • Bhatti Z, Norsworthy J, Szombathy T. Loperamide metabolite-induced cardiomyopathy and QTc prolongation. Clin Toxicol Forthcoming. [cited 2017 Mar 28]. DOI: 10.1080/15563650.2017.1304555
  • Eggleston W, Nacca N, Marraffa JM. Loperamide toxicokinetics: serum concentrations in the overdose setting. Clin Toxicol. 2015;53:495–496.
  • Eggleston W, Clark KH, Marraffa JM. Loperamide abuse associated with cardiac dysrhythmia and death. Ann Emerg Med. 2016;69:83–86.
  • Marraffa JM, Holland MG, Sullivan RW, et al. Cardiac conduction disturbance after loperamide abuse. Clin Toxicol. 2014;52:952–957.
  • Eggleston W, Marraffa JM, Stork CM, et al. Notes from the field: cardiac dysrhythmias after loperamide abuse – New York, 2008–2016. MMWR Morb Mortal Wkly Rep. 2016;65:1276–1277.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.